Targeting Discoidin Domain Receptors DDR1 and DDR2 overcomes matrix‐mediated tumor cell adaptation and tolerance to BRAF‐targeted therapy in melanoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Targeting Discoidin Domain Receptors DDR1 and DDR2 overcomes matrix‐mediated tumor cell adaptation and tolerance to BRAF‐targeted therapy in melanoma ; day:27 ; month:12 ; year:2021 ; extent:22
EMBO molecular medicine / European Molecular Biology Organization ; (27.12.2021) (gesamt 22)
- Creator
-
Berestjuk, Ilona
Lecacheur, Margaux
Carminati, Alexandrine
Diazzi, Serena
Rovera, Christopher
Prod’homme, Virginie
Ohanna, Mickael
Popovic, Ana
Mallavialle, Aude
Larbret, Frédéric
Pisano, Sabrina
Audebert, Stéphane
Passeron, Thierry
Gaggioli, Cédric
Girard, Christophe A.
Deckert, Marcel
Tartare‐Deckert, Sophie
- DOI
-
10.15252/emmm.201911814
- URN
-
urn:nbn:de:101:1-2021122714123992421545
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
2025-08-15T07:30:28+0200
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Berestjuk, Ilona
- Lecacheur, Margaux
- Carminati, Alexandrine
- Diazzi, Serena
- Rovera, Christopher
- Prod’homme, Virginie
- Ohanna, Mickael
- Popovic, Ana
- Mallavialle, Aude
- Larbret, Frédéric
- Pisano, Sabrina
- Audebert, Stéphane
- Passeron, Thierry
- Gaggioli, Cédric
- Girard, Christophe A.
- Deckert, Marcel
- Tartare‐Deckert, Sophie
Other Objects (12)
Targeting CDK 2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Optimizing the treatment of BRAF mutant melanoma
Novel combination therapies for BRAF-mutant melanoma
Mushroom lectin overcomes hepatitis B virus tolerance via TLR6 signaling
Clinical significance of BRAF mutations in metastatic melanoma
The immune-related role of BRAF in melanoma
The role of BRAF V600 mutation in melanoma
B-Raf specific antibody responses in melanoma patients
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
Targeting CDK 2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Optimizing the treatment of BRAF mutant melanoma
Novel combination therapies for BRAF-mutant melanoma
Mushroom lectin overcomes hepatitis B virus tolerance via TLR6 signaling
Clinical significance of BRAF mutations in metastatic melanoma
The immune-related role of BRAF in melanoma
The role of BRAF V600 mutation in melanoma
B-Raf specific antibody responses in melanoma patients
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
Targeting CDK 2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Optimizing the treatment of BRAF mutant melanoma
Novel combination therapies for BRAF-mutant melanoma
Mushroom lectin overcomes hepatitis B virus tolerance via TLR6 signaling
Clinical significance of BRAF mutations in metastatic melanoma
The immune-related role of BRAF in melanoma
The role of BRAF V600 mutation in melanoma
B-Raf specific antibody responses in melanoma patients